Skip to content
Qinlock(ripretinib)
Qinlock (ripretinib) is a small molecule pharmaceutical. Ripretinib was first approved as Qinlock on 2020-05-15. It is used to treat gastrointestinal stromal tumors in the USA. It has been approved in Europe to treat gastrointestinal stromal tumors. It is known to target mast/stem cell growth factor receptor Kit.
Download report
Favorite
FDA Novel Drug Approvals 2020
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
Trade Name
FDA
EMA
Qinlock
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ripretinib
Tradename
Company
Number
Date
Products
QINLOCKDeciphera PharmaceuticalsN-213973 RX2020-05-15
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
qinlockNew Drug Application2020-10-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
gastrointestinal stromal tumorsEFO_0000505D046152C49.A
Agency Specific
FDA
EMA
Expiration
Code
RIPRETINIB, QINLOCK, DECIPHERA PHARMS
2027-05-15ODE-298
2025-05-15NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Ripretinib, Qinlock, Deciphera Pharms
111855352040-12-30DP
113958182040-12-30DP
115769032040-12-30DP
116125912040-12-30DP
109669662040-08-12U-3153
112666352040-08-12U-3330
113445362040-08-12U-3381
114263902040-08-12U-3416
114330562040-08-12U-3423
115293362040-08-12U-3382
115344322040-08-12U-3442
115769042040-08-12U-3537
RE487312032-06-07U-3219
84611792032-06-07DS, DP
81881132030-07-27DS, DP
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
L01EX: Other protein kinase inhibitors in atc
L01EX19: Ripretinib
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A333311
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8011
Systemic mastocytosisD034721C96.2111
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRIPRETINIB
INNripretinib
Description
Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. It is taken by mouth. Ripretinib inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from growing.
Classification
Small molecule
Drug classretinol derivatives; tyrosine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Identifiers
PDB
CAS-ID1442472-39-0
RxCUI
ChEMBL IDCHEMBL4216467
ChEBI ID
PubChem CID71584930
DrugBankDB14840
UNII ID9XW757O13D (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KIT
KIT
Organism
Homo sapiens
Gene name
KIT
Gene synonyms
SCFR
NCBI Gene ID
Protein name
mast/stem cell growth factor receptor Kit
Protein synonyms
c-Kit protooncogene, CD117, p145 c-kit, PBT, Piebald trait protein, Proto-oncogene c-Kit, proto-oncogene tyrosine-protein kinase Kit, Tyrosine-protein kinase Kit, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein
Uniprot ID
Mouse ortholog
Kit (16590)
mast/stem cell growth factor receptor Kit (Q8C8K9)
Variants
Clinical Variant
No data
Financial
Qinlock - Zai Lab
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 285 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1 adverse events reported
View more details